SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness.
Aminobutyrates
Angiotensin Receptor Antagonists
/ therapeutic use
Angiotensin-Converting Enzyme Inhibitors
/ pharmacology
Biphenyl Compounds
/ therapeutic use
Cost-Benefit Analysis
Diabetes Mellitus, Type 2
/ drug therapy
Drug Combinations
Heart Failure
Humans
Sodium-Glucose Transporter 2 Inhibitors
/ pharmacology
Stroke Volume
/ physiology
Tetrazoles
/ therapeutic use
Treatment Outcome
Ventricular Dysfunction, Left
/ drug therapy
Journal
American journal of cardiovascular drugs : drugs, devices, and other interventions
ISSN: 1179-187X
Titre abrégé: Am J Cardiovasc Drugs
Pays: New Zealand
ID NLM: 100967755
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
accepted:
06
10
2021
pubmed:
18
11
2021
medline:
6
5
2022
entrez:
17
11
2021
Statut:
ppublish
Résumé
Heart failure (HF) represents a major global health and economic burden with still unacceptably high morbidity and mortality rates. In recent decades, novel therapeutic opportunities with a significant impact on HF outcomes have been introduced in addition to angiotensin-converting enzyme (ACE) inhibitors, β-blockers, and mineralocorticoid receptor antagonists. These include drugs such as ivabradine, sacubitril-valsartan, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. The availability of an extremely large pharmacological armamentarium to face this chronic global disease highlights the importance of assessing cost effectiveness to promote sustainable healthcare. In light of the recent approval of SGLT-2 inhibitors for the treatment of HF with reduced ejection fraction, including in individuals without type 2 diabetes mellitus, the aim of this review was to provide an updated comparative evaluation of the efficacy and cost effectiveness of different pharmacological treatments for the prevention (stage A) and treatment of asymptomatic (stage B) and symptomatic (stages C-D) left ventricular dysfunction.
Identifiants
pubmed: 34786655
doi: 10.1007/s40256-021-00508-3
pii: 10.1007/s40256-021-00508-3
doi:
Substances chimiques
Aminobutyrates
0
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Biphenyl Compounds
0
Drug Combinations
0
Sodium-Glucose Transporter 2 Inhibitors
0
Tetrazoles
0
sacubitril
17ERJ0MKGI
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
263-270Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Ponikowski P, et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1(1):4–25.
pubmed: 28834669
doi: 10.1002/ehf2.12005
Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail. 2019;21(11):1306–25.
pubmed: 31523902
doi: 10.1002/ejhf.1594
Mamas MA, et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur J Heart Fail. 2017;19(9):1095–104.
pubmed: 28470962
doi: 10.1002/ejhf.822
Roger VL. Epidemiology of heart failure. Circ Res. 2013;113(6):646–59.
pubmed: 23989710
pmcid: 3806290
doi: 10.1161/CIRCRESAHA.113.300268
McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.
pubmed: 34447992
doi: 10.1093/eurheartj/ehab368
Anker SD, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385(16):1451–61.
pubmed: 34449189
doi: 10.1056/NEJMoa2107038
McGuire DK, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes. JAMA Cardiol. 2021;6(2):148.
pubmed: 33031522
doi: 10.1001/jamacardio.2020.4511
SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327(10):685–91.
doi: 10.1056/NEJM199209033271003
Exner DV, Dries DL, Waclawiw MA, Shelton B, Domanski MJ. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction. J Am Coll Cardiol. 1999;33(4):916–23.
pubmed: 10091816
doi: 10.1016/S0735-1097(98)00675-5
Pfeffer MA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327(10):669–77.
pubmed: 1386652
doi: 10.1056/NEJM199209033271001
Yancy CW, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239.
pubmed: 23747642
doi: 10.1016/j.jacc.2013.05.019
Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129–2200m.
pubmed: 27206819
doi: 10.1093/eurheartj/ehw128
Cavallari I, et al. The vicious circle of left ventricular dysfunction and diabetes: from pathophysiology to emerging treatments. J Clin Endocrinol Metab. 2020;105(9):e3075–89.
doi: 10.1210/clinem/dgaa427
Cavallari I, Maddaloni E. Cardiovascular effects of SGLT-2 inhibitors: what we have learned from cardiovascular outcome trials and what we still need to understand. Diabetes Metab Res Rev. 2019;35(4):e3124.
pubmed: 30604504
doi: 10.1002/dmrr.3124
Cosentino F, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.
pubmed: 31497854
doi: 10.1093/eurheartj/ehz486
Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302.
pubmed: 2057034
doi: 10.1056/NEJM199108013250501
Swedberg K, Idanpaan-Heikkila U, Remes J. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316(23):1429–35.
doi: 10.1056/NEJM198706043162301
Packer M, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure. Circulation. 2002;106(17):2194–9.
pubmed: 12390947
doi: 10.1161/01.CIR.0000035653.72855.BF
Dargie HJ, Lechat P. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13.
doi: 10.1016/S0140-6736(98)11181-9
Hjalmarson A, et al. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–7.
doi: 10.1016/S0140-6736(99)04440-2
Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709–17.
pubmed: 10471456
doi: 10.1056/NEJM199909023411001
Pitt B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21.
pubmed: 12668699
doi: 10.1056/NEJMoa030207
Zannad F, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.
pubmed: 21073363
doi: 10.1056/NEJMoa1009492
Abdulla J, et al. Effect of angiotensin-converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction–a meta-analysis. Eur J Heart Fail. 2006;8(1):90–6.
pubmed: 16054435
doi: 10.1016/j.ejheart.2005.03.006
Packer M, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–8.
pubmed: 11386263
doi: 10.1056/NEJM200105313442201
Böhm M, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013;102(1):11–22.
pubmed: 22575988
doi: 10.1007/s00392-012-0467-8
McMurray JJVV, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
pubmed: 25176015
doi: 10.1056/NEJMoa1409077
McMurray JJVV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
pubmed: 31535829
doi: 10.1056/NEJMoa1911303
Kosiborod MN, et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF Trial. Circulation. 2020;141(2):90–9.
pubmed: 31736335
doi: 10.1161/CIRCULATIONAHA.119.044138
Packer M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24.
pubmed: 32865377
doi: 10.1056/NEJMoa2022190
Zannad F, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet (London, England). 2020;396(10254):819–29.
doi: 10.1016/S0140-6736(20)31824-9
Anker SD, et al. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status. Circulation. 2021;143(4):337–49.
pubmed: 33175585
doi: 10.1161/CIRCULATIONAHA.120.051824
Petrie MC, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323(14):1353.
pubmed: 32219386
pmcid: 7157181
doi: 10.1001/jama.2020.1906
Solomon SD, et al. Effect of dapagliflozin in patients with hfref treated with sacubitril/valsartan. JACC Heart Fail. 2020;8(10):811–8.
pubmed: 32653447
doi: 10.1016/j.jchf.2020.04.008
Dewan P, et al. Efficacy and safety of sodium–glucose co-transporter inhibition according to left ventricular ejection fraction in DAPA-HF. Eur J Heart Fail. 2020;22(7):1247–58.
pubmed: 32539224
doi: 10.1002/ejhf.1867
EuroQol—a new facility for the measurement of health-related quality of life. Health Policy (New. York). 16(3):199–208 (1990)
Yoshida Y, Cheng X, Shao H, Fonseca VA, Shi L. A systematic review of cost-effectiveness of sodium-glucose cotransporter inhibitors for type 2 diabetes. Curr Diab Rep. 2020;20(4):12.
pubmed: 32166504
doi: 10.1007/s11892-020-1292-5
Arbel R, Aboalhasan E, Hammerman A, Azuri J. Sodium-glucose cotransporter 2 inhibitors for prevention of heart failure events in patients with type 2 diabetes mellitus: a cost per outcome analysis. Clin Drug Investig. 2020;40(7):665–9.
pubmed: 32449083
doi: 10.1007/s40261-020-00929-z
McMurray JJV, McGuire A, Davie AP, Hughes D. Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction. Eur Heart J. 1997;18(9):1411–5.
pubmed: 9458446
doi: 10.1093/oxfordjournals.eurheartj.a015466
Tsevat J, et al. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol. 1995;26(4):914–9.
pubmed: 7560617
doi: 10.1016/0735-1097(95)00284-1
P. Shekelle, et al. Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness. Evid Rep Technol Assess (Summ). 2003;(82):1–6.
Phillips KA. Health and economic benefits of increased β-blocker use following myocardial infarction. JAMA. 2000;284(21):2748.
pubmed: 11105180
doi: 10.1001/jama.284.21.2748
McEwan P, et al. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. Eur J Heart Fail. 2020;22(11):2147–56.
pubmed: 32749733
doi: 10.1002/ejhf.1978
Savira F, et al. Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. Eur J Prev Cardiol. 2020;28(9):975–82.
pubmed: 34402872
doi: 10.1177/2047487320938272
Yao Y, Zhang R, An T, Zhao X, Zhang J. Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China. ESC Heart Fail. 2020;7(6):3582–92.
pmcid: 7754897
doi: 10.1002/ehf2.12844
McMurray JJV, et al. Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Heart. 2018;104(12):1006–13.
pubmed: 29269379
doi: 10.1136/heartjnl-2016-310661
Gandjour A, Ostwald DA. Sacubitril/Valsartan (LCZ696): a novel treatment for heart failure and its estimated cost effectiveness, budget impact, and disease burden reduction in Germany. Pharmacoeconomics. 2018;36(10):1285–96.
pubmed: 30054868
doi: 10.1007/s40273-018-0688-4
Cavallari I, Maddaloni E, Grigioni F. Implementing the treatment of heart failure with SGLT-2 inhibitors and sacubitril-valsartan: does money matter? Eur J Prev Cardiol. 2020. https://doi.org/10.1093/eurjpc/zwaa153 .
doi: 10.1093/eurjpc/zwaa153
Arbel R, Aboalhasan E, Hammerman A, Azuri J. Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysis. Eur. J Prev Cardiol. 2020. https://doi.org/10.1093/eurjpc/zwaa136 .
doi: 10.1093/eurjpc/zwaa136
Griffiths A, Paracha N, Davies A, Branscombe N, Cowie MR, Sculpher M. The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective. Heart. 2014;100(13):1031–6.
pubmed: 24634022
doi: 10.1136/heartjnl-2013-304598
Kansal AR, et al. Cost-effectiveness of ivabradine for heart failure in the United States. J Am Heart Assoc. 2016;5(5):e003221. https://doi.org/10.1161/JAHA.116.003221 .
doi: 10.1161/JAHA.116.003221
pubmed: 27153871
pmcid: 4889192
Glick H, et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. J Card Fail. 1995;1(5):371–80.
pubmed: 12836712
doi: 10.1016/S1071-9164(05)80006-5
Ekman M, Zethraeus N, Jönsson B. Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial. Pharmacoeconomics. 2001;19(9):901–16.
pubmed: 11700777
doi: 10.2165/00019053-200119090-00002
Weintraub WS, et al. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation. 2005;111(9):1106–13.
pubmed: 15723981
doi: 10.1161/01.CIR.0000157146.86758.BC